Pfizer

Metsera Inc. has announced an amended merger agreement with Pfizer, valued at up to $86.25 per share, comprising $65.60 upfront and a contingent value right (CVR) of up to $20.65 based on milestones. The Metsera Board unanimously recommends shareholder approval, citing optimal value and deal certainty. This decision follows concerns raised by the U.S. Federal Trade Commission regarding a previous deal with Novo Nordisk. The board prioritizes the Pfizer merger due to its expectation of swift closure and immediate value delivery to shareholders.

Metsera, Inc. is facing a lawsuit from Pfizer amid Pfizer’s proposed acquisition of Metsera. Metsera stated they disagree with the allegations and will address them in court. The lawsuit introduces complexity to the acquisition process, potentially delaying or derailing the deal. Experts suggest the suit may involve intellectual property, regulatory compliance, or financial disclosures. The outcome depends on the strength of Pfizer’s claims and Metsera’s defense. The filing with the SEC highlights risks including litigation expenses, regulatory hurdles, and the success of pipeline products.